Published: July 14, 2026
By: Jonathan Gardner
In a high-stakes maneuver designed to disrupt the lucrative immunology market, Avere Therapeutics has announced its intention to go public through a reverse merger. The move, which signals a significant shift in the competitive landscape for psoriasis and inflammatory disease treatments, is anchored by the acquisition of global rights to a promising drug candidate licensed from Chinese pharmaceutical powerhouse Hansoh. This development positions Avere as a direct challenger to established blockbuster therapies, including AbbVie’s Skyrizi and Johnson & Johnson’s Icotyde.
The Mechanics of the Merger: A New Chapter for NextCure
The structural foundation of this transition lies in the transformation of NextCure. Following a series of research setbacks that hindered its oncology pipeline, NextCure initiated a significant restructuring in 2024, which included substantial workforce reductions. This lean operating model allowed the company to preserve capital, providing the necessary runway to reach the second half of 2026.
Under the terms of the merger, NextCure shareholders will retain a modest equity stake in the newly combined entity—just over 1%. However, the deal includes a sophisticated financial instrument known as a contingent value right (CVR). This mechanism allows legacy NextCure shareholders to capture up to 90% of the proceeds should any of the company’s original oncology assets be out-licensed or sold in the future. Once the transaction closes in the latter half of 2026, the combined organization will debut on the Nasdaq exchange under the ticker symbol "AVRX."
Strategic Acquisition: The AVR-001 Pipeline
The crown jewel of the new entity is AVR-001, a therapeutic candidate that Avere has secured through a major licensing agreement with Hansoh Pharma. The financial terms of the deal underscore the high expectations surrounding the asset: Avere has committed $120 million in upfront fees, with a potential for an additional $2.18 billion in milestone payments, alongside tiered sales royalties.
AVR-001 is designed to address the IL-23 pathway, a critical target in modern immunology. Hansoh has already moved aggressively, initiating a Phase 2b clinical trial in China, with results anticipated by 2027. Avere is mirroring this urgency, having filed the necessary regulatory documentation to commence U.S. testing. The company plans to launch its own parallel Phase 2b trial in the United States in 2027.
"We are focused on rapidly delivering a once-weekly oral IL-23 therapy that combines best-in-class convenience with efficacy competitive with other emerging oral IL-23 therapies," said Avere CEO Andrew Cheng. The company has confirmed that its current funding position is sufficient to sustain operations through the completion of these Phase 2b trials, the initiation of a global Phase 3 study, and the commencement of a Phase 2b trial targeting ulcerative colitis.
Chronology of Development and Market Entry
The trajectory of Avere’s entry into the market is defined by a rapid, globalized clinical strategy:
- 2024: NextCure undergoes significant restructuring, reducing staff and streamlining operations to survive until 2026.
- Early 2026: Negotiation and finalization of the licensing deal for AVR-001 from Hansoh Pharma.
- July 2026: Formal announcement of the reverse merger between Avere and NextCure.
- Second Half 2026: Expected closing of the merger and Nasdaq debut under "AVRX."
- 2027: Expected data readout from Hansoh’s Phase 2b trial in China; planned initiation of U.S. Phase 2b trial by Avere.
- 2028-2029: Anticipated timeline for global Phase 3 enrollment and potential regulatory filings.
The Immunology Landscape: The Shift to Oral Delivery
The immunology market is currently dominated by biologic injectables that have transformed the standard of care for patients with psoriasis, psoriatic arthritis, and inflammatory bowel diseases. The IL-23 cytokine, a key driver of inflammation, has been a primary target for over a decade.
Johnson & Johnson’s Stelara pioneered this space in 2009, and subsequent therapies such as Skyrizi, Tremfya, and Ilumya have raised the efficacy bar. However, these treatments primarily require periodic injections, which can be a barrier to patient adherence and lifestyle integration.
The industry is now undergoing a seismic shift toward oral therapies. J&J’s recent launch of Icotyde, a daily oral peptide, signaled a move toward greater patient convenience. Avere’s AVR-001 seeks to leapfrog the competition by offering a "once-weekly" dosing schedule. If clinical data confirms that this frequency can be achieved without compromising the high efficacy associated with current biologics, AVR-001 could capture significant market share from both traditional injectables and daily oral alternatives.
Supporting Data: Why IL-23 Matters
The cytokine IL-23 is essential in the activation of T-helper 17 (Th17) cells, which produce pro-inflammatory cytokines like IL-17. In patients with psoriasis, the overproduction of these cells leads to the characteristic itchy, red, and scaly skin lesions. By effectively blocking the IL-23 receptor, drugmakers can achieve "near-clear" or "clear" skin in a significant percentage of patients.
The clinical success of drugs like Skyrizi has validated the market demand for high-potency IL-23 inhibition. Avere’s bet is that while current oral therapies provide convenience, the dosing frequency of "once-daily" remains a burden compared to a "once-weekly" option. By focusing on this specific pharmacological gap, Avere is aiming to carve out a premium position in the multi-billion dollar dermatology and gastroenterology markets.
Implications for the Sector
The Avere-NextCure deal reflects three broader trends currently reshaping the biopharmaceutical industry:
- The Globalization of R&D: The licensing of AVR-001 from a Chinese developer is a prime example of the "In-China, For-Global" strategy. Chinese firms, long viewed as manufacturing partners, are increasingly becoming the source of primary innovation, forcing Western biotech firms to forge early partnerships to secure access to global rights.
- Reverse Mergers as a Capital Necessity: With the IPO window for early-stage biotech remaining volatile, reverse mergers into existing public entities have become a favored path for companies looking to bypass the costs and delays of a traditional public offering while providing liquidity to existing shareholders.
- The "Oral-First" Race: The race to replace injectable biologics with oral small molecules or peptides is the defining competition of the late 2020s. Companies that can bridge the "potency gap"—where oral drugs historically struggled to match the efficacy of injectables—will likely dictate the future of the autoimmune market.
Looking Ahead: Risks and Opportunities
While the potential for AVR-001 is significant, Avere faces a challenging road. Developing an oral peptide that remains stable in the gastrointestinal tract and achieves high systemic bioavailability is notoriously difficult. Avere must prove in its upcoming Phase 2b trials that AVR-001 can indeed match the high efficacy standards set by the incumbents while maintaining a safety profile that allows for long-term, chronic use.
Furthermore, the integration of NextCure’s legacy operations and the management of the CVRs require significant operational discipline. Should the clinical trials for AVR-001 encounter delays or safety signals, the company’s capital-intensive strategy—which relies on funding through 2027—could be severely tested.
As Avere Therapeutics transitions into its new life as a public entity, the eyes of the immunology community will be fixed on the 2027 data readouts. Whether the company succeeds in redefining the standard of care for psoriasis remains to be seen, but the strategy is clear: by leveraging Chinese innovation and the efficiency of the reverse merger, Avere is positioning itself as a lean, high-velocity challenger in the most competitive segment of modern medicine.
